NaMuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic (NDM) disorders.1
NaMuscla is the first licensed antimyotonic demonstrated to:
• Control symptoms of myotonia in adult patients with NDM.1,2
• Improve patient’s daily lives.1,2
• Provide generally well-tolerated, long-term myotonia relief.3
Myotonia is more than an inability to relax muscles.4,5
Myotonia is a chronic, lifelong condition that impacts NDM patients on a daily basis.4,5
Untreated myotonia can have dramatic consequences for NDM patients.
Myotonia restricts everyday life.
NaMuscla: 1st licensed antimyotonic demonstrated to control symptomatic myotonia.1-2
Demonstrated effective relief from NDM-related myotonia.1,2
Functional benefits vs placebo irrespective of NDM channelopathy.1,2
NaMuscla: Suitable for long-term use.3
Long-term experience in patients with NDM – retrospective chart review (4.8y).3
NaMuscla: A daily, long-term treatment for relief from myotonia.3
NaMuscla composition & dosing.1
Each patient should be given a Patient Alert card before initiating treatment with NaMuscla®
Healthcare Professional Education Guide and Patient Alert cards are available from: www.medicines.org.uk
References: 1. NaMuscla Summary of Product Characteristics. Lupin Europe GmbH. 2. Vicart S, et al. Neuromuscular Disorders 2021; 31(11):1124-1135. 3. Suetterlin KJ, et al. JAMA Neurology 2015; 72(12):1531-1533. 4. Trivedi JR, et al. Brain 2013; 136:2189-2200. 5. Trip J, et al. J Neurol 2009; 256:939-947. 6. Statland JM, et al. JAMA 2012; 308:(13):1357-1365.
167mg Hard Capsules
|Product Licence Number||EU/1/18/1325/003|
|Lupin Product Code||509874|
|Pack Size||100 Capsules|
NaMuscla Supply Chain
At Lupin Healthcare we recognise the importance of continued supply of branded medicines and are committed to the highest quality standards. With this in mind we supply NaMuscla through all three major UK wholesalers.
UK-LUP-2208-00003 DOP: September 2022